# NATURAL INHIBITORS OF $\beta\text{2-Adrenergic Receptor: A}$ Computational Study for Targeting GPCR-Mediated Diseases



#### Sepideh Jafari, Joanna Bojarska


Chemistry Department, Institute of Ecological and Inorganic Chemistry, Technical University of Lodz, Poland <u>sepideh.jafari@dokt.p.lodz.pl</u>; joanna.bojarska@p.lodz.pl

## BACKGROUND

G-protein-coupled receptors (GPCRs) regulate essential physiological processes by converting extracellular signals into intracellular responses. Among them, the  $\beta$ 2-Adrenergic Receptor ( $\beta$ 2-AR) is crucial for smooth muscle relaxation, bronchodilation, and cardiovascular regulation, making it a key target for conditions such as asthma, hypertension, and chronic obstructive pulmonary disease. While synthetic drugs effectively target  $\beta$ 2-AR, they often lead to adverse effects and drug resistance, highlighting the need for alternative therapeutic approaches.

#### METHODS

This study employed molecular docking using AutoDock 4.6 to investigate the interactions of natural compounds like; ephedrine, quercetin, catechin, and resveratrol with  $\beta$ 2-AR. The receptor's 3D structure (PDB ID: 2RHI) was obtained, and docking simulations assessed binding energy, hydrogen bonding, and stabilizing interactions between each ligand and the




## RESULTS

Natural	Binding	H.bind
Compounds	Energy	
Ephedrine	-4.66	3
Quercetin	-5.44	5
Catechin	-5.34	4
Resveratrol	-5.01	3

The results showed that ephedrine formed hydrogen bonds with key  $\beta$ 2-AR residues, aligning with previous findings. Quercetin exhibited strong binding interactions, reinforcing its potential as a natural inhibitor. Catechin and resveratrol also demonstrated stabilizing interactions, though their binding affinities were lower than quercetin.

### CONCLUSION

These findings suggest that natural compounds could serve as safer and more effective alternatives to synthetic drugs in targeting GPCR-related diseases. The use of molecular docking further highlights their potential in drug discovery and the development of bio-inspired therapeutic strategies.





- [1] Johnson M. Paediatr Respir Rev. 2006;7(Suppl 1):S3–S7.
- [2] Liu Y, He Y, Wang K. Phytother Res. 2019;33(3):571–582.
- [3] Cherezov V, Rosenbaum DM, Hanson MA, et al. Science. 2007;318(5854):1258–1265.
- [4] Kim YJ, et al. J Mol Graph Model. 2017;76:1-9.
- [5] Wang L, et al. Biomed Pharmacother. 2021;134:111066.